Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganirelix for LH pulsatility in PCOS
NCT05751252Phase 1Completed
- Sponsor
- CHU de Lille
- Start
- Apr 2024
- Primary completion
- Feb 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ganirelix in polycystic ovary syndrome (PCOS) (2 arms), sponsored by CHU de Lille. Primary endpoint: Serum Luteinizing Hormone Level. Started Apr 2024; status: completed.
02
Drugs
ganirelix
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT05751252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751252.